Regen Biopharma’s lead NR2F6 agonist combined with Cannabidiol (CBD) could treat Inflammatory Bowel Disease

Regen BioPharma’s researches have combined its lead NR2F6 small molecule agonist with Cannabidiol (CBD) to provide a dynamic therapy for treating inflammatory bowel disease (IBD), and it could work.

Regen believes that CBD may increase its small molecule therapies for autoimmune disorders, in this case specifically IBD, as currently, there are a number of pre-clinical and clinical studies being conducted by other companies regarding pain management that suggest potential benefits of CBD.

Regen explained out in the press release that IBD is a disease caused by persistent and chronic inflammation of the gastrointestinal tract and is a term that refers to both ulcerative colitis and Crohn’s disease. Current treatments include non-specific immune suppressors such as steroids as well as newer drugs recently approved by the FDA.

Good argument to go with finding further solutions is the IBD market size, which is estimated at $6.7 billion global and projected to be $7.6 billion by 2023.There are currently no non-steroidal therapies  available to IBD sufferers.

Harry Lander, President and Chief Scientific Officer of Regen is satisfied with the company’s ex-vivo studies with its small molecule agonist RG-NAH005, support moving the drug into animal studies where we can measure the effect of the drug on different diseases. “We believe incorporating CBD in our studies will allow us to potentially strengthen positive outcomes for patients,” he said in the statement.

David Koos, Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics, is also pleased that RG-NAH005 has shown a safety profile that allows Regen to move it into animal studies. “We are enthusiastic that combining CBD with our small molecule agonist will potentially make our small molecule therapy for IBD more dynamic is its approach to treating this disease,” he added.